Repurposing topical MC903, an FDA-approved vitamin D analog, to trigger skin-derived bile acid synthesis and generate systemic anti-inflammatory effects in lupus nephritis.
Developing CART4-34, a novel CAR T cell therapy that selectively eliminates IGHV4-34+ pathogenic B cells in lupus while sparing healthy B cells and avoiding broad immunosuppression.
Advancing engineered CAR and CAAR T cell therapies across multiple autoimmune diseases through clinical trials, preclinical development, and industry partnerships.
Developing next-generation mRNA-LNP therapeutics that selectively modulate or deplete pathogenic immune cells to treat type 1 diabetes, lupus, multiple sclerosis, and other severe autoimmune conditions.
